The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2018 | PROMISE: MGUS/SMM screening study
Irene Ghobrial, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses the new PROMISE study (NCT03689595), aiming to determine the clinical and genomic alterations present in individuals with monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) through screening those at high risk due to a family history or ethnicity. Dr Ghobrial, speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, shares the biggest myeloma screening study ever run to help prevent progression from occurring by catching the disease at an early stage.
